Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod alpha and pembrolizumab in NSCLC and HNSCC
NCT03625323Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Feb 2019
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by Immutep Limited. Started Feb 2019; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03625323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625323.